Isracann Biosciences Inc.
ISCNF
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 215.60K | 399.20K | 418.70K | 693.50K | 386.60K |
| Depreciation & Amortization | 8.10K | 8.20K | 8.20K | 8.30K | 8.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.70K | 407.40K | 426.90K | 701.80K | 395.00K |
| Operating Income | -223.70K | -407.40K | -426.90K | -701.80K | -395.00K |
| Income Before Tax | -245.10K | -2.15M | -487.80K | -695.80K | -376.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -245.10K | -2.15M | -487.80K | -695.80K | -376.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -245.10K | -2.15M | -487.80K | -695.80K | -376.40K |
| EBIT | -223.70K | -407.40K | -426.90K | -701.80K | -395.00K |
| EBITDA | -215.60K | -399.20K | -418.70K | -693.50K | -386.60K |
| EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 158.46M | 152.77M | 146.08M | 146.08M | 146.08M |
| Average Diluted Shares Outstanding | 158.46M | 152.77M | 146.08M | 146.08M | 146.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |